Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE

User menu

  • Log out
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log out
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
    • Special Collections
  • EDITORIAL BOARD
    • Editorial Board
    • ECR Advisory Board
    • Journal Staff
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
    • Accessibility
  • SUBSCRIBE
PreviousNext
Behavioral/Systems/Cognitive

CNS Glucagon-Like Peptide-1 Receptors Mediate Endocrine and Anxiety Responses to Interoceptive and Psychogenic Stressors

Kimberly P. Kinzig, David A. D'Alessio, James P. Herman, Randall R. Sakai, Torsten P. Vahl, Helmer F. Figueiredo, Erin K. Murphy and Randy J. Seeley
Journal of Neuroscience 16 July 2003, 23 (15) 6163-6170; https://doi.org/10.1523/JNEUROSCI.23-15-06163.2003
Kimberly P. Kinzig
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David A. D'Alessio
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James P. Herman
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randall R. Sakai
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten P. Vahl
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Helmer F. Figueiredo
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin K. Murphy
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randy J. Seeley
1Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and Departments of 2Psychiatry and 3Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0559
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Central nucleus of the amygdala injection sites. After the completion of the experiments involving CeA-cannulated rats, the animals were killed and given injections of cresyl violet via the CeA cannula. Brains were subsequently sectioned (50 μm/section), and cannula placement was verified. Black dots within the CeA of each bottom diagram represent injection sites for the rats with correctly placed cannulas. Rats whose cannulas were not in the CeA were excluded from the data analyses (n = 6 of 25 removed).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Paraventricular nucleus of the hypothalamus injection sites. After the completion of the experiments involving PVN-cannulated rats, the animals were killed and given injections of cresyl violet via the PVN cannula. Brains were subsequently sectioned (50 μm/section), and cannula placement was verified. Black dots within the PVN of each bottom diagram represent injection sites for the rats with correctly placed cannulas. Rats whose cannulas were not in the PVN were excluded from the data analyses (n = 5 of 22 removed).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    A, Plasma ACTH levels after i3vt administration of GLP-1 (0.1, 1.0, or 10 μg) or saline. Plasma ACTH was significantly elevated in response to all three doses of GLP-1 at 15, 30, and 60 min. At 120 min after injection, only 10 μg of GLP-1 resulted in significantly elevated ACTH. B, Plasma CORT after i3vt administration of GLP-1 (0.1, 1.0, or 10 μg). All three doses resulted in significant elevations of CORT at 15, 30, and 60 min after injection. When animals received the highest dose, plasma CORT remained significantly elevated at 120 min. *All three treatment groups significantly different from saline; p < 0.05. #Highest dose (10 μg) significantly different from saline; p < 0.05.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    A, Plasma ACTH after intraperitoneal administration of GLP-1. Fifteen minutes after injection (10, 100, and 500 μg/kg or saline), the highest dose of GLP-1 resulted in a significant increase in plasma ACTH (p < 0.05). There were no other differences between GLP-1 and saline treatment. B, Plasma CORT after intraperitoneal administration of GLP-1. Intraperitoneal administration of GLP-1 (10, 100, and 500 μg/kg) did not elevate plasma CORT. *Highest dose (500 μg/kg) significantly different from saline; p < 0.05.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    A, Plasma ACTH after CRH receptor antagonism and i3vt GLP-1. CRH receptor antagonism attenuated GLP-1-induced elevations in plasma ACTH. Plasma ACTH was significantly lower in rats treated with the CRH receptor antagonist astressin before 1 μg of GLP-1 administered i3vt. B, Plasma CORT after CRH receptor antagonism and i3vt GLP-1. CRH receptor antagonism attenuated GLP-1-induced elevations in plasma CORT. Plasma CORT was significantly lower in rats treated with the CRH receptor antagonist astressin before 1 μg of GLP-1 administered i3vt (p < 0.01 at 15, 30, and 60 min).

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    A, Plasma ACTH after GLP-1 receptor antagonism and intraperitoneal LiCl. Plasma ACTH levels were significantly elevated after intraperitoneal administration of LiCl. This effect was attenuated by pretreatment with the GLP-1 receptor antagonist des-His1,Glu9-exendin-4 (exendin). At 15, 30, 60, and 120 min, saline plus LiCl resulted in significantly elevated ACTH compared with saline plus saline (p < 0.001; p < 0.001; p < 0.01; p < 0.01, respectively), compared with exendin plus saline (p < 0.001 at 15 min; p < 0.01 at 30 and 60 min; not significantly different at 120 min), and compared with exendin plus LiCl (p < 0.001 at 15 min; p < 0.01 at 30 min; p < 0.05 at 60 min; no difference at 120 min). B, Plasma CORT after GLP-1 receptor antagonism and intraperitoneal LiCl. At 15, 30, and 60 min, saline plus LiCl resulted in significantly elevated CORT compared with saline plus saline (p < 0.001; p < 0.001; p < 0.01, respectively), compared with exendin plus saline (p < 0.001 at 15 and 30 min; p < 0.01 at 60 min), and compared with exendin plus LiCl (p < 0.001 at 15 and 30 min; p < 0.05 at 60 min). There were no significant differences in CORT levels at 120 min.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    A, Plasma ACTH after GLP-1 receptor antagonism before placement on an isolated open arm of the elevated plus maze. At 15, 30, and 60 min after EPM stress, rats that were pretreated with exendin had significantly lower plasma ACTH levels than did saline-treated rats. B, Plasma CORT after GLP-1 receptor antagonism before placement on an isolated open arm of the elevated plus maze. At 15, 30, and 60 min after EPM stress, rats that were pretreated with exendin had significantly lower plasma CORT levels than did saline-treated rats. *Significantly different from saline; p < 0.01.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    A, Plasma CORT levels in response to administration of GLP-1 directly into the CeA. There was no significant effect of either dose (0.2 or 1.0 μg) on plasma CORT at 60 min after infusion compared with saline. B, Plasma CORT levels in response to administration of GLP-1 directly into the PVN. Plasma CORT (0.2 or 1.0 μg) was significantly elevated at 60 min after infusion of either 0.2 or 1.0 μg of GLP-1 compared with saline; *p < 0.05.

Back to top

In this issue

The Journal of Neuroscience: 23 (15)
Journal of Neuroscience
Vol. 23, Issue 15
16 Jul 2003
  • Table of Contents
  • About the Cover
  • Index by author
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CNS Glucagon-Like Peptide-1 Receptors Mediate Endocrine and Anxiety Responses to Interoceptive and Psychogenic Stressors
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
CNS Glucagon-Like Peptide-1 Receptors Mediate Endocrine and Anxiety Responses to Interoceptive and Psychogenic Stressors
Kimberly P. Kinzig, David A. D'Alessio, James P. Herman, Randall R. Sakai, Torsten P. Vahl, Helmer F. Figueiredo, Erin K. Murphy, Randy J. Seeley
Journal of Neuroscience 16 July 2003, 23 (15) 6163-6170; DOI: 10.1523/JNEUROSCI.23-15-06163.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
CNS Glucagon-Like Peptide-1 Receptors Mediate Endocrine and Anxiety Responses to Interoceptive and Psychogenic Stressors
Kimberly P. Kinzig, David A. D'Alessio, James P. Herman, Randall R. Sakai, Torsten P. Vahl, Helmer F. Figueiredo, Erin K. Murphy, Randy J. Seeley
Journal of Neuroscience 16 July 2003, 23 (15) 6163-6170; DOI: 10.1523/JNEUROSCI.23-15-06163.2003
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • GLP-1
  • interoceptive stress
  • psychogenic stress
  • glucocorticoids
  • central nucleus of the amygdala
  • paraventricular nucleus
  • anxiety

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

  • Musical Expertise Induces Audiovisual Integration of Abstract Congruency Rules
  • The Laminar Development of Direction Selectivity in Ferret Visual Cortex
  • Individual Differences in Amygdala-Medial Prefrontal Anatomy Link Negative Affect, Impaired Social Functioning, and Polygenic Depression Risk
Show more Behavioral/Systems/Cognitive
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Accessibility
(JNeurosci logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.